In today’s session Intrexon Corp (XON) recorded an unusually high (500) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the January, 2017 put, expecting serious XON decrease. With 500 contracts traded and 13434 open interest for the Jan, 17 contract, it seems this is a quite bearish bet. The option with symbol: XON170120P00020000 closed last at: $0.35 or 12.5% down. About 41,673 shares traded hands. Intrexon Corp (NYSE:XON) has declined 15.06% since April 18, 2016 and is downtrending. It has underperformed by 19.49% the S&P500.
Intrexon Corp (NYSE:XON) Ratings Coverage
Out of 6 analysts covering Intrexon (NYSE:XON), 4 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 67% are positive. $70 is the highest target while $28 is the lowest. The $47.40 average target is 51.68% above today’s ($31.25) stock price. Intrexon has been the topic of 10 analyst reports since July 27, 2015 according to StockzIntelligence Inc. JP Morgan downgraded Intrexon Corp (NYSE:XON) rating on Tuesday, August 11. JP Morgan has “Overweight” rating and $55 price target. The company was initiated on Tuesday, May 3 by JMP Securities. The rating was maintained by Wunderlich with “Buy” on Monday, October 19. Wunderlich maintained Intrexon Corp (NYSE:XON) rating on Monday, July 27. Wunderlich has “Buy” rating and $70 price target. Mizuho maintained it with “Neutral” rating and $28 target price in Monday, January 25 report. The firm has “Underperform” rating given on Tuesday, August 11 by Mizuho. Bank of America initiated the stock with “Neutral” rating in Wednesday, October 14 report. The stock has “Buy” rating given by Wunderlich on Tuesday, August 11. The stock has “Neutral” rating given by Mizuho on Wednesday, November 11. The stock of Intrexon Corp (NYSE:XON) has “Buy” rating given on Monday, September 21 by Stifel Nicolaus.
According to Zacks Investment Research, “Intrexon Corporation is a biotechnology company. It provides synthetic biology services. The Company designs and produces modular DNA control systems and applications for human therapeutics, protein production, industrial products, agricultural biotechnology, and animal sciences. Its technologies include the UltraVector gene design and fabrication platform; Cell Systems Informatics; LEAP-cell identification and selection, and mAbLogix-antibody discovery. Intrexon Corporation is based in Germantown, Maryland.”
Insitutional Activity: The institutional sentiment increased to 1.3 in 2016 Q2. Its up 0.18, from 1.12 in 2016Q1. The ratio improved, as 37 funds sold all Intrexon Corp shares owned while 40 reduced positions. 18 funds bought stakes while 68 increased positions. They now own 98.85 million shares or 1.45% less from 100.31 million shares in 2016Q1.
Geode holds 0% or 315,004 shares in its portfolio. Parametric Assoc Limited Liability Corporation accumulated 125,960 shares or 0% of the stock. Ironbridge Capital Ltd Partnership holds 0.19% or 177,930 shares in its portfolio. Sabby Mgmt Ltd Liability Co has invested 0.15% of its portfolio in Intrexon Corp (NYSE:XON). Tower Rech Cap Ltd Liability (Trc), a New York-based fund reported 463 shares. Zurcher Kantonalbank (Zurich Cantonalbank) has 146,537 shares for 0.05% of their US portfolio. Bluemountain Capital Mngmt Lc reported 30,862 shares or 0.02% of all its holdings. Fifth Third Bancshares has 0% invested in the company for 415 shares. Parallax Volatility Advisers Limited Partnership holds 110,329 shares or 0.01% of its portfolio. Atlantic Gru Limited Liability Company has 14,661 shares for 0% of their US portfolio. Wfg Advisors Lp accumulated 150 shares or 0% of the stock. Cacti Asset Mgmt Limited Liability Company reported 10,000 shares or 0.03% of all its holdings. The California-based Blackrock Institutional Tru Co Na has invested 0.01% in Intrexon Corp (NYSE:XON). Rhumbline Advisers holds 54,293 shares or 0% of its portfolio. Commonwealth Equity Svcs Inc reported 12,806 shares or 0% of all its holdings.
Insider Transactions: Since August 29, 2016, the stock had 1 buy, and 0 insider sales for $104,484 net activity. On Monday, August 29 the insider Nimrodi Nir bought $104,484.
Intrexon Corporation forms collaborations to create biologically based products and processes using synthetic biology. The company has a market cap of $3.64 billion. The Firm designs, manufactures and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. It currently has negative earnings. The Company’s synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale.
XON Company Profile
Intrexon Corporation (Intrexon), incorporated on June 1, 2010, forms collaborations to create biologically based products and processes using synthetic biology. The Company’s domestic activities are in California, Florida, Maryland, and Virginia, and its primary international activities are in Belgium and Hungary. The Firm designs, manufactures and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company’s synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale. The Company’s technologies combine the principles of precision engineering, statistical modeling, automation and production at an industrial scale. The Company’s technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing, or LEAP, and ActoBiotics platform.
More recent Intrexon Corp (NYSE:XON) news were published by: Fool.com which released: “3 Reasons Intrexon Corp. Stock Could Rise” on November 15, 2016. Also Nasdaq.com published the news titled: “Commit To Purchase Intrexon Corp At $17.50, Earn 16.6% Using Options” on October 25, 2016. Prnewswire.com‘s news article titled: “AquaBounty Technologies Inc. (“AquaBounty” or the “Company”) Filing of Form 10 …” with publication date: November 07, 2016 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.